51. Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe
- Author
-
Zenon Huczek, Helge Möllmann, Wouter J. Kikkert, Luis C. L. Correia, Silvia Scarano, Iván J. Núñez-Gil, Sergio Raposeiras-Roubín, Masa-aki Kawashiri, Fiorenzo Gaita, Christoph Liebetrau, Claudio Moretti, Dongfeng Zhang, Francesca Giordana, Alberto Garay, Antonio Montefusco, Albert Ariza-Solé, Toshiharu Fujii, Hiroki Shiomi, Emad Abu-Assi, Jorge F. Saucedo, Jing-Yao Fan, Neriman Osman, Takuya Nakahayshi, Masakazu Yamagishi, Emilio Alfonso, Oliver Kalpak, Fabrizio D'Ascenzo, Sasko Kedev, José Ramón González-Juanatey, Xiao Wang, Michal Kowara, Belén Terol, Stephen B. Wilton, Xiantao Song, Ioanna Xanthopoulou, José María García-Acuña, Shaoping Nie, Yuji Ikari, Yalei Chen, José P.S. Henriques, Krzysztof J. Filipiak, Danielle A. Southern, Tetsuma Kawaji, Yan Yan, Kenji Sakata, Dimitrios Alexopoulos, Amsterdam Cardiovascular Sciences, and Cardiology
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,Ticagrelor ,Prasugrel ,Internationality ,Ticlopidine ,Far East ,Hemorrhage ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Ethnicity ,Humans ,East Asia ,030212 general & internal medicine ,Registries ,Acute Coronary Syndrome ,Stroke ,Aged ,Retrospective Studies ,Geographic area ,Asia, Eastern ,business.industry ,Clopidogrel ,P2Y12 receptor ,Platelet inhibitor ,Europe ,Female ,Follow-Up Studies ,Middle Aged ,Platelet Aggregation Inhibitors ,Purinergic P2Y Receptor Antagonists ,Treatment Outcome ,Cardiology and Cardiovascular Medicine ,medicine.disease ,Surgery ,Conventional PCI ,business ,medicine.drug - Abstract
Background: In the setting of the Acute Coronary Syndrome (ACS), differences in response to prasugrel and ticagrelor between East Asian and European patients have not been investigated yet. Methods: This is a sub-analysis of the "BleeMACS registry". Patients admitted for ACS and underwent PCI from between 2012 and 2014 were stratified first according to their provenance, Europe vs. East Asia (China and Japan), and then by country. The adjusted rate of 1-year serious bleeding - safety end-point-and 1-year death/re-infarction -effectiveness endpoint-of the new P2Y12r inhibitors were compared. Results: Data of 10004 patients in Europe and 2332 patients in East Asia were collected. At baseline prior stroke (6% vs 9%, p
- Published
- 2016